{"title":"坚持每日口服PrEP的个人是否需要Lenacapavir ？","authors":"Xin Niu, Paul K. Drain","doi":"10.1001/jama.2024.22995","DOIUrl":null,"url":null,"abstract":"This Viewpoint discusses the potential advantages of injectable preexposure prophylaxis (PrEP) drugs such as lenacapavir for persons unable to adhere to daily oral HIV PrEP and highlights ways in which lenacapavir and expanded PrEP options could offer tailored and effective ways to better meet the diverse needs of at-risk individuals.","PeriodicalId":518009,"journal":{"name":"JAMA","volume":"81 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Is Lenacapavir Needed for Individuals Adherent to Daily Oral PrEP?\",\"authors\":\"Xin Niu, Paul K. Drain\",\"doi\":\"10.1001/jama.2024.22995\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This Viewpoint discusses the potential advantages of injectable preexposure prophylaxis (PrEP) drugs such as lenacapavir for persons unable to adhere to daily oral HIV PrEP and highlights ways in which lenacapavir and expanded PrEP options could offer tailored and effective ways to better meet the diverse needs of at-risk individuals.\",\"PeriodicalId\":518009,\"journal\":{\"name\":\"JAMA\",\"volume\":\"81 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAMA\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1001/jama.2024.22995\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1001/jama.2024.22995","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Is Lenacapavir Needed for Individuals Adherent to Daily Oral PrEP?
This Viewpoint discusses the potential advantages of injectable preexposure prophylaxis (PrEP) drugs such as lenacapavir for persons unable to adhere to daily oral HIV PrEP and highlights ways in which lenacapavir and expanded PrEP options could offer tailored and effective ways to better meet the diverse needs of at-risk individuals.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
